AUSTIN, Texas & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple types of cancers, today announced that it will present an abstract at the International Society for Cellular Therapy Annual Meeting (ISCT) in Montreal, and a company overview at the Bloom Burton & Co. Healthcare Investor Conference in Toronto, both on Thursday, May 3.
At the ISCT, Dr. Chris Helsen, Director of Platform Development, will be presenting during the “Cancer Immunotherapy” breakout plenary on May 3, 11:00am – 12:15pm ET. The abstract is titled T cells engineered with T-Cell Antigen Coupler (TAC) receptors display robust efficacy against solid and liquid tumor xenografts in the absence of any toxicity.
At the Bloom Burton & Co. conference, President and Chief Executive Officer Dr. Paul Lammers will provide an overview of Triumvira and the improvements the company is making over current therapies with its novel immuno-oncology platform T Cell-Antigen Coupler (TAC). Dr. Lammers will also be giving updates on Triumvira’s lead drug, CD19-TAC01, which is targeted to enter clinical development in Q1 2019 for the treatment of patients with CD19 positive B-cell malignancies. Dr. Lammers will be presenting May 3, at 3:00pm ET and will be available for private meetings during the day.
About the ISCT
The International Society of Cellular Therapy
is a global society of clinicians, regulators, technologists, and
industry partners with a shared vision to translate cellular therapy
into safe and effective therapies to improve patients' lives. ISCT
Members gain access to an influential global community of peers,
experts, and organizations invested in cell therapy. ISCT offers a
unique collaboration between academia, regulatory bodies, and industry
partners in cell therapy translation.
About the Bloom Burton & Co. Conference
The Bloom Burton
& Co. Healthcare Investor Conference brings together U.S., Canadian and
international investors who are interested in the latest developments in
the Canadian healthcare sector. Attendees will have an opportunity to
obtain corporate updates from the premier Canadian publicly traded and
private companies through presentation and private meetings.
About Triumvira Immunologics
Triumvira Immunologics, Inc.
(“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr.
Jonathan Bramson, Tier I Canada Research Chair of Translational Cancer
Immunology at McMaster University, and Bloom Burton & Co., a life
sciences focused investment bank in Toronto, with the vision of
developing novel T cell therapies that are safer and more efficacious
than current gene therapy cancer treatments, including chimeric antigen
receptor (CAR) and engineered T cell receptor (TCR) therapies. Our
proprietary T cell Antigen Coupler (TAC) technology recruits the entire
natural T cell receptor and is independent of the Major
Histocompatibility Complex (MHC), allowing for the development of better
therapies for a broader range of patients with solid or liquid
malignancies and also with diseases other than cancer. With operations
spanning North America, our corporate offices are located in Austin,
Texas, with our research facilities in Hamilton, Ontario. For more
information, visit www.triumvira.com
or send email inquiries to partners@triumvira.com.
